Case Studies

2024-11-05

Stable Cell Lines

CHO stable cell lines were developed for recombinant antibody production, achieving over 3 g/L expression. Analyses of yield, stability, mycoplasma, purity, and affinity confirmed antibody quality. Additionally, a stable line for Varicella-Zoster Virus gE protein was validated, demonstrating biopharmaceutical versatility

2024-11-05

Bacillus subtilis

Two case studies highlight Bacillus subtilis as an efficient host for recombinant protein production. Protein A (20 mg/L, >90% purity) and Protein B (1 mg/L, >95% purity) demonstrate its scalability and reliability.

2024-11-05

Preparation of MHC-Peptide Complex Proteins

HLA-I protein and β2M were expressed and purified in E. coli, followed by refolding to form stable HLA/β2M/peptide complexes (pMHC). The addition of streptavidin (SA) enabled the formation of stable tetramers for downstream applications.

2024-11-05

E. coli Expression System

This study demonstrates the optimization of E. coli expression systems for recombinant protein and antibody fragment production. Strategies included host strain selection, periplasmic expression for proper folding, and refolding inclusion bodies into active soluble proteins. Results showcase high-quality protein expression and QC validation.

2024-11-04

Insect-Baculovirus Expression System Case Study

This case study demonstrates the use of the insect-baculovirus expression system for efficient production of recombinant proteins. The approach achieved high yields with proper folding and post-translational modifications, showcasing its reliability for complex protein expression.

2024-11-04

Mammalian HEK293 Expression

The results show that the SARS-CoV-2 S protein expressed in mammalian cells achieved high yields during purification, with clear target protein bands observed in elution fractions (E1-E8) and minimal impurities.

2024-10-21

XtenCHO™ High-Density Expression System

AtaGenix's XtenCHO™ high-density expression system demonstrates exceptional proliferation and yield advantages in therapeutic antibody production. Cells cultured in this system maintain high density and viability over 15 days, ensuring healthy growth. The system shows strong adaptability and production efficiency across various antibodies, providing robust support for efficient and stable therapeutic antibody manufacturing.